Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

Status

NO_LONGER_AVAILABLE

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT05170685

Enrollment

Unknown

Registered

2021-12-28

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.

BIOLOGICALNivolumab plus Relatlimab FDC

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026